275 related articles for article (PubMed ID: 35603206)
1. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
Xu Z; Chen S; Zhang Y; Liu R; Chen M
Front Immunol; 2022; 13():869759. PubMed ID: 35603206
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of m5C Methylation Regulatory Genes and Tumor Microenvironment in Prostate Cancer.
Yu G; Bao J; Zhan M; Wang J; Li X; Gu X; Song S; Yang Q; Liu Y; Wang Z; Xu B
Front Immunol; 2022; 13():914577. PubMed ID: 35757739
[TBL] [Abstract][Full Text] [Related]
3. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
[TBL] [Abstract][Full Text] [Related]
4. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
Wang W; Li T; Xie Z; Zhao J; Zhang Y; Ruan Y; Han B
J Transl Med; 2024 Jan; 22(1):57. PubMed ID: 38221616
[TBL] [Abstract][Full Text] [Related]
5. 5-methylcytosine RNA methylation regulators affect prognosis and tumor microenvironment in lung adenocarcinoma.
Liu T; Hu X; Lin C; Shi X; He Y; Zhang J; Cai K
Ann Transl Med; 2022 Mar; 10(5):259. PubMed ID: 35402591
[TBL] [Abstract][Full Text] [Related]
6. m5C regulator-mediated modification patterns and tumor microenvironment infiltration characterization in colorectal cancer: One step closer to precision medicine.
Chen B; Xi Y; Zhao J; Hong Y; Tian S; Zhai X; Chen Q; Ren X; Fan L; Xie X; Jiang C
Front Immunol; 2022; 13():1049435. PubMed ID: 36532062
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
[TBL] [Abstract][Full Text] [Related]
8. Development and Validation of a Machine Learning Prognostic Model of m5C Related immune Genes in Lung Adenocarcinoma.
Cao X; Ji Y; Li J; Liu Z; Chen C
Cancer Control; 2024; 31():10732748241237414. PubMed ID: 38537151
[TBL] [Abstract][Full Text] [Related]
9. The signature of cuproptosis-related immune genes predicts the tumor microenvironment and prognosis of prostate adenocarcinoma.
Yao K; Zhang R; Li L; Liu M; Feng S; Yan H; Zhang Z; Xie D
Front Immunol; 2023; 14():1181370. PubMed ID: 37600770
[TBL] [Abstract][Full Text] [Related]
10. Development of the expression and prognostic significance of m
Xu G; Li C; Di Z; Yang Y; Liang L; Yuan Q; Yang Q; Dong X; Xu S; Wu G
Cancer Med; 2023 Mar; 12(6):7667-7681. PubMed ID: 36464884
[TBL] [Abstract][Full Text] [Related]
11. m5C regulator-mediated methylation modification phenotypes characterized by distinct tumor microenvironment immune heterogenicity in colorectal cancer.
Chen Z; Li Q; Lin Y; Lin S; Gao J; Chen S
Sci Rep; 2023 Jul; 13(1):11950. PubMed ID: 37488178
[TBL] [Abstract][Full Text] [Related]
12. Establishment of an age- and tumor microenvironment-related gene signature for survival prediction in prostate cancer.
Chen L; Zhang M; Zhou J; Zhang L; Liang C
Cancer Med; 2022 Nov; 11(22):4374-4388. PubMed ID: 35535438
[TBL] [Abstract][Full Text] [Related]
13. ALYREF m5C RNA methylation reader predicts bladder cancer prognosis by regulating the tumor immune microenvironment.
Pan W; Liu X; Liu S
Medicine (Baltimore); 2024 Apr; 103(14):e37590. PubMed ID: 38579085
[TBL] [Abstract][Full Text] [Related]
14. Contribution of m5C RNA Modification-Related Genes to Prognosis and Immunotherapy Prediction in Patients with Ovarian Cancer.
Liu Y; Liu S; Yan L; Zhang Q; Liu W; Huang X; Liu S
Mediators Inflamm; 2023; 2023():1400267. PubMed ID: 38022687
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage Lung Adenocarcinoma.
Tian L; Wang Y; Tian J; Song W; Li L; Che G
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047493
[TBL] [Abstract][Full Text] [Related]
16. The Value of m5C-Related lncRNAs in the Prognostic Assessment and Immunotherapy of Stomach Adenocarcinoma.
He C; Zhu X; Kong F; Zhang X; Chai X; Zou C; Zhao D
Biomed Res Int; 2022; 2022():2747799. PubMed ID: 35711526
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of obesity related genes signature based on microenvironment phenotypes in prostate adenocarcinoma.
Liang L; Shang J; Zhang Y; Xu Y; Zhouteng Y; Wen J; Zhao Y; Feng N; Zhao R
Aging (Albany NY); 2023 Oct; 15(19):10168-10192. PubMed ID: 37788005
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy.
Luo Y; Liu X; Lin J; Zhong W; Chen Q
Math Biosci Eng; 2022 Aug; 19(11):11345-11366. PubMed ID: 36124593
[TBL] [Abstract][Full Text] [Related]
19. Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment.
Hu B; Zhang X; Zhu S; Wang C; Deng Z; Wang T; Wu Y
Eur J Med Res; 2024 Jan; 29(1):92. PubMed ID: 38297388
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA profile study identifies an immune-related lncRNA prognostic signature for prostate adenocarcinoma.
Liang L; Xia W; Yao L; Wu Q; Hua L; Cheng G; Wang Z; Zhao R
Int Immunopharmacol; 2021 Dec; 101(Pt A):108267. PubMed ID: 34740081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
